Abstract
Background
ALL is the most common childhood malignancy. The children with ALL are treated with methotrexate (MTX) based chemotherapy protocols. MTX causes unpredictable serious hepatic and renal side effects. Silymarin has antioxidant and anti-inflammatory activities and stimulates tissue regeneration. This study aims to evaluate the protective effects of Silymarin on MTX-based chemotherapy-induced Hepatic and renal toxicity in children with ALL.
Patients and Methods
80 children with newly diagnosed ALL were enrolled in the study. They were randomly divided into two groups. Group I included 40 children with ages ranging from 4–13 years and the mean age of 6.85± 2.89 years, who received Silymarin 420 mg/day in 3 divided doses for one week after each MTX dose. Group II included 40 children, with ages ranging from 4–12 years and the mean age of 7.30±2.6 years, who received placebo for one week after MTX therapy. For all patients liver functions including serum bilirubin, total proteins, albumin, globulin and albumin-globulin ratio, alkaline phosphatase, ALT and AST, prothrombin time and activity and renal functions including blood urea and serum creatinine, serum cystatin C and urinary N-acetyl-beta-D-glucosaminidase were done to assess hepatic and renal toxicity before and after chemotherapy.
Results
There were no significant differences between group I and II as regard liver and renal functions before chemotherapy. After chemotherapy, there were significantly higher values of ALT and AST and alkaline phosphatase, and significantly lower Prothrombin activity in group II compared with group I. No significant differences between group I and II were found in total bilirubin, serum protein, and albumin levels. There was significantly lower blood urea, serum creatinine, and cystatin C and urinary N-acetyl-beta-D-glucosaminidase in group I compared with group II.
Conclusion
Silymarin improved some hepatic and renal functions in children with ALL who received MTX-based chemotherapy protocols. Recommendations: Extensive multicenter studies could be recommended to prove the hepatic and renal protective effects of Silymarin in patients with ALL who received MTX-based chemotherapy protocols.
Introduction
Acute Lymphoblastic Leukemia (ALL) is the most common childhood malignancy, representing one-third of pediatric cancers.1
Methotrexate (MTX) is a key drug in the curative regimen of children with ALL.2 MTX is a potent hepatotoxic agent that causes injury of the liver associated with impaired liver functions.3 The underlying mechanism of MTX hepatotoxicity remains unclear, however, MTX causes oxidative stress in liver tissue as it is metabolized and stored in hepatocytes in a polyglutamates form which delays the clearance of MTX providing a depot that extends the duration of exposure to the drug.4
Methotrexate is also nephrotoxic due to precipitation of MTX or its metabolites in the renal tubules causing obstruction and diminution of renal clearance with a consequent prolongation of MTX high levels. High MTX levels may, in turn, lead to an ineffective rescue by leucovorin and an enhancement of MTX toxicity. Also, MTX and its metabolites are relatively insoluble in acid urine.5
MTX hepatic and renal toxicity can lead to discontinuation or reduction of chemotherapy doses which may affect the overall prognosis, so it is essential to search for certain drugs to reduce MTX side effects especially hepatic and renal toxicities.6,7
Silymarin is an active extract from the seeds of the plant milk thistle (Silybum marianum) and is commonly known as Milk Thistle. The most prevalent component of the Silymarin complex is silybin or Silibinin (50–60% of silymarin) which is the most active photochemical and is widely responsible for benefits of silymarin. Besides silybin, considerable amounts of other flavonolignans are present in silymarin complex, namely silly Christin (20%), silydianin (10%), isosilybin (5%), dehydrosilybin, and a few flavonoids, mainly taxifolin.8,9 Silymarin has cytoprotective effects against several classes of hepatotoxic drugs like acetaminophen and galactosamine and nephrotoxic drugs like cisplatin;10 furthermore, a study of Ghaffari et al. 201111 showed significantly lower ALT and AST levels in rats receiving MTX plus Silymarin than rats receiving MTX and placebo. The protective effects of orally administered Silymarin have also been demonstrated in patients with ALL under MTX-based chemotherapy.12,13
The purpose of the work was to study the protective effects of Silymarin on MTX-based chemotherapy-induced hepatic and renal toxicity in children with acute lymphoblastic leukemia.
Subjects and Methods
This randomized study was conducted on 80 children with newly diagnosed ALL, admitted to Hematology Unit, Pediatric Department, Tanta University Hospital. It obtained the preventive approval from ethical committee of Research Centre in Tanta University and written consent from parents of enrolled children.
Randomization was done using sequentially numbered, opaque, sealed envelopes. So the patients were randomly divided into two equal groups:
Group I
40 children with ALL including 24 males and 16 females with ages ranging from 4–12 years and the mean age of 6.85 ± 2.89 years. They were treated with methotrexate-based treatment protocol14–18 and delayed Ca leucovorin rescue according to methotrexate levels.19 Silymarin 420 mg/day, (In the form of Legalon- MEDA Pharma GmbH- tablets 140 mg per tablet one hour before each meal (3 times daily) or Hepaticum syrup (Medical Union Pharmaceuticals, Egypt) in case of inability to swallow the tablet form; (each 5 ml of Hepaticum contains 50 mg Silymarin) was added in 3 divided doses one hour before each meal for one week after each MTX dose.7,20
Group II
40 children with ALL including 26 males and 14 females with their age ranging from 4–12 years and the mean age of 7.30 ± 2.69 years. They were treated with MTX based treatment protocol14–18 and delayed Ca leucovorin rescue according to MTX levels19 and placebo for one week after each methotrexate dose.
Inclusion criteria
Children with newly diagnosed acute lymphoblastic leukemia who were treated with the methotrexate-based treatment protocol.
Exclusion criteria
Patients with acute lymphoblastic leukemia with hepatitis A, B or C.
All patients were subjected to a full history taking, and clinical examination with a special account of fever, pallor, purpura, bone ache, hepatosplenomegaly, generalized lymphadenopathy and neurological features. Tools and laboratory investigations for diagnosis of ALL were performed according to clinical presentation. They always included complete blood count, BM aspiration with morphological, cytochemical smears and immunophenotyping and was based on the presence of ≥ 20% blast cells in BM according to WHO proposal and MPO negative staining and immunophenotyping consistent with ALL, spinal puncture with liquor examination.21–24
Bone marrow aspiration was done under complete aseptic technique. Smears of direct BM aspirate were prepared, stained with Lieshman stain for morphologic study and cytochemical stains with Sudan black and Myeloperoxidase. Immunophenotyping was performed using the following panel of fluorescein isothiocyanate/phycoerythrin-conjugated monoclonal antibodies: Lymphoid T-cell markers (CD2, CD3, CD5, CD7), Lymphoid B-cell markers (CD10, CD19, CD20, CD22) and Myeloid cell markers (CD13, CD33).21–24
Liver and renal functions to assess methotrexate hepatic and renal toxicity before and after chemotherapy
A venous blood sample of 5.8 ml was collected from each patient and delivered into three tubes: 1 ml of 20 uL EDTA solution for complete blood count including differential WBCs which was done on Leishman stained peripheral blood smear with evaluation using ERMA PCE-210 N cell –counter from Erma, Inc. Japan;25 1.8 ml blood into tube containing 0.4 ml sodium citrate for prothrombin time and activity;26 3 ml into a plain tube for other liver functions including serum bilirubin, total protein, albumin, globulin and A/G ratio,27 serum alkaline phosphatase, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)28 and renal functions including blood, urea serum creatinine and blood urea nitrogen (BUN),29 and serum cystatin C. Cystatin was measured by latex particle-enhanced turbidimetric immunoassay (PETIA) on Hitachi 7600 auto-analyzer (Hitachi Co., Tokyo, Japan) using HiSense kit (HBI Co., Anyang, Korea)30 and urinary N-acetyl-beta-D-glucosaminidase (NAG) which was estimated kinetically using Sigma reagents (USA).31 Serum for serum cystatin C and early morning urine samples for urinary NAG were collected, centrifuged, aliquoted and frozen at − 20 °C. Samples were thawed and mixed thoroughly just before the assay to avoid erroneous results of repeated freeze/thaw cycles.32
Protocol of treatment used in the studied ALL patients
Induction (6 weeks)
IV Vincristine 1.5mg/kg/m2/week (days 0, 7, 14, 21, 28, 35), Doxorubicin 25mg/m2/week IV infusion (days 0, 7, 14, 21, 28, 35), asparginase 6000 u/m2 SC on alternate days (10 doses) and oral prednisone 40 mg/m2/day for 6weeks. On day 21, BM aspiration was done; If BM blast cells is more than 5 %, we add etoposide 100 mg/m2/dose IV (days 22, 25, 29), cyclophosphamide 750mg/m2/dose IV infusion (days 22, 25, 29), aracytin 100/m2/dose IV (days 22, 25, 29), and methotrexate 5g/m2 over 4 hours on day 28.13
Consolidation (9 weeks)
IV methotrexate 1gm/m2/dose over 24 hour infusion on days 0, 21, 42 and 63, oral mercaptopurine 60 mg/m2 daily on days 0–13 and 28–41, IV vincristine 1.5 mg/m2 on days 14, 21, 42 and 49, PEG asparaginase 2,500 units/m2 IM on days 14 and 22, cyclophosphamide 750 mg/m2/dose IV infusion on days 0 and 28, aracytin 100/m2/dose IV on days 1–4, 8–11, 29–32 and 36–39 and age-adjusted intrathecal methotrexate on days 1,8,15 and 22.14,15
Interim maintenance (6 weeks)
IV Vincristine 1.5 mg/m2 on days 0, 10, 20, 30, 40, IV methotrexate starting dose of 100 mg/m2/dose over 10–15 minutes on day 0 thereafter escalate by 50 mg/m2/dose on days 10, 20, 30 and 40, PEG asparaginase 2,500 units/m2 IM on days 1 and 21 and age-adjusted intrathecal methotrexate on days 0 and 30.15
Delayed–intensification (6 weeks)
Oral dexamethasone 10 mg/m2/day days 1–7 and 14–21, IV vincristine 1.5 mg/m2 on days 0, 7 and 14, IM or IV pegylated L-asparaginase 2500 u/m2 on day 4, doxorubicin 25 mg/m2 IV push on days 0, 7 and 14, IV cyclophosphamide 1gm/m2 over 30 minutes on day 28, oral 6-thioguanine 60 mg/m2 on days 28–41, aracytin 75mg/m2 on days 29–32 and 36–39 and age-adjusted intrathecal methotrexate on day 28.14
Maintenance (30 months)
Weekly IV methotrexate 20 mg/m2, prednisone 120 mg/m2/day for five days every three weeks, vincristine 2 mg/m2 IV every three weeks, oral 6-mercaptopurine 50 mg/m2/day for 14 days every three weeks and age-adjusted intrathecal methotrexate every 18 weeks.17
Dose and duration of Ca-leucovorin
18 The groups I and II received the same doses and length of leucovorin rescue which was started 48 hours after the start of MTX infusion in dose of 10 mg/m2 orally or IV every 6 hours but adjusted after that according to the MTX levels in each patient separately as follows:
If methotrexate level is < 0.5 μmol/L: Ca leucovorin 15 mg/m2 is given every 3 hours (4 doses) then15 mg/m2 every 6 hours (8 doses).
If methotrexate level is 0.5–1 μmol/L: Ca leucovorin 30 mg/m2 is given every 3 hours until MTX level becomes less than 0.1 μmol/L then 15 mg/m2 every 6 hours (8 doses).
If methotrexate level is > 1 μmol/L: Ca leukovorin 50–100 mg/m2 is given every 3 hours until MTX level becomes less than 0.1 μmol/L then 15 mg/m2 every 6 hours (8 doses).
Statistics
The collected data were organized, tabulated and statistically analyzed using SPSS software statistical computer package version 13. For qualitative data, the comparison between two groups was made using Chi-square test (X2). For comparison between means of two different groups, parametric analysis (t-test) and non-parametric analysis (Mann-Whitney U test) were used. Significance was adapted at P< 0.05 for interpretation of results of tests of significance.33
Results
There were no statistically significant differences between studied groups as regard age and sex. Pallor, purpura, hepatomegaly, and splenomegaly represent the main presenting clinical manifestations in the studied patients at the time of diagnosis with no significant differences between Group I and II regarding clinical presentations. (Table 1).
Table 1.
Comparison between studied groups as regard main clinical presentations and laboratory data at the time of diagnosis.
| Clinical presentations | Group I (No=40) | Group II (No=40) | X2 | P-value | |
|---|---|---|---|---|---|
|
| |||||
| Age (years) | |||||
| Range | 4–13 | 4–12 | 0.259 | 0.614 | |
| Mean + SD | 6.85 ± 2.89 | 7.30 ± 2.69 | |||
|
| |||||
| Sex | |||||
| Male | 24 (60% | 26 (65%) | 0.107 | 0.500 | |
| Female | 16 (40%)) | 14 (35%) | |||
|
| |||||
| Fever | 22 (55%) | 20 (50%) | 0.100 | 0.500 | |
|
| |||||
| Pallor | 31 (77.5%) | 32 (80%) | 0.025 | 0.653 | |
|
| |||||
| Purpura | 28 (70%) | 30 (75%) | 2.667 | 0.095 | |
|
| |||||
| CNS infiltration | 2 (5%) | 2 (5%) | 0.023 | 0.756 | |
|
| |||||
| Bone ache | 18 (45%) | 16 (40%) | 0.114 | 0.500 | |
|
| |||||
| Hepatomegaly | 38 (95%) | 34(85%) | 3.137 | 0.091 | |
|
| |||||
| Splenomegaly | 40 (100%) | 36 (90%) | 5.714 | 0.054 | |
|
| |||||
| Lymphadenopathy | 28 (70%) | 26(65%) | 1.758 | 0.160 | |
|
| |||||
| Immunophenotyping | |||||
| Early pre-B-ALL | 30 | 28 | X2 3.034 |
0.219 | |
| Pre-B-ALL | 6 | 10 | |||
| T-ALL | 4 | 2 | |||
|
| |||||
| Hb (g/dl) | Range | 5.9 – 11.5 | 3 – 12.9 | 3.105 | 0.086 |
|
| |||||
| Mean ± SD | 7.92 ±1.86 | 6.69 ± 2.49 | |||
|
| |||||
| MCV(fL) | Range | 70 – 99 | 70 – 99 | 1.249 | 0.271 |
|
| |||||
| Mean ± SD | 81.81 ± 7.57 | 84.55 ± 7.96 | |||
|
| |||||
| MCH (pg) | Range | 26 – 31 | 28 – 33 | 1.136 | 0.293 |
|
| |||||
| Mean ± SD | 29.41 ± 1.34 | 29.9 ± 1.59 | |||
|
| |||||
| MCHC (%) | Range | 29 – 34.5 | 31 – 35 | 1.647 | 0.207 |
|
| |||||
| Mean ± SD | 31.9 ± 1.66 | 32.5 ± 1.28 | |||
|
| |||||
| WBCs (103/mm3) | Range | 1.9 – 121 | 2.7 – 130 | 1.997 | 0.166 |
|
| |||||
| Mean ± SD | 28.61 ± 86.63 | 32.15 ± 90.07 | |||
|
| |||||
| Platelets (103/mm3) | Range | 20 – 293 | 10 – 191 | 1.426 | 0.240 |
|
| |||||
| Mean ± SD | 83.7± 63.92 | 72.3 ± 48.33 | |||
|
| |||||
| Peripheral blood Blast cells % | Range | 0 – 86 | 0 – 90 | 4.124 | 0.09 |
|
| |||||
| Mean ± SD | 37.25 ± 24.85 | 40.8 ±27.82 | |||
CNS: Central Nervous System. Hb: Hemoglobin, WBCS: White blood cells, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration.
There were normocytic normochromic anemia, thrombocytopenia, leukocytosis and increased blast cells in peripheral blood in studied patients with no significant differences between Group I and II as regard parameters of complete blood count (Table 1).
There were no statistically significant differences between studied groups as regard immunophenotyping at the time of diagnosis (Table 1).
There were no statistically significant differences between Group I and II as regard liver functions before chemotherapy (Table 2).
Table 2.
Comparison between studied groups as regard liver functions before the start of chemotherapy.
| Parameters | Group I (No=40) | Group II (No=40) | t. test | P. value | |
|---|---|---|---|---|---|
| Serum ALT (U/L) | Range | 13–77 | 16–87 | 2.766 | 0.104 |
| Mean ± SD | 24.35 ± 15.76 | 35.10 ± 14.52 | |||
| Serum AST (U/L) | Range | 17–57 | 14–64 | 3.609 | 0.065 |
| Mean ± SD | 23.95 ± 11.76 | 27.25 ± 19.58 | |||
| Total serum Bilirubin (mg/dl) | Range | 0.42 – 1.2 | 0.4 – 0.9 | 0.323 | 0.573 |
| Mean ± SD | 0.76 ± 0.2 | 0.73 ± 0.14 | |||
| Direct bilirubin (mg/dl) | Range | 0.15 – 0.4 | 0.11 – 0.3 | 1.417 | 0.241 |
| Mean ± SD | 0.26 ± 0.08 | 0.24 ± 0.05 | |||
| Indirect bilirubin (mg/dl) | Range | 0.20 – 0.8 | 0.28 – 0.7 | 0.100 | 0.754 |
| Mean ± SD | 0.49 ± 0.17 | 0.48 ± 0.15 | |||
| Alkaline phosphatase (U/L) | Range | 112–209 | 109 – 219 | 0.118 | 0.734 |
| Mean ± SD | 155.40 ± 31.24 | 151.65 ±37.63 | |||
| Albumin (g/dl) | Range | 3.1 – 4.3 | 3–4.7 | 0.033 | 0.858 |
| Mean ± SD | 3.79 ± 0.34 | 3.77 ± 0.52 | |||
| Total protein (g/dl) | Range | 6–8.3 | 5.4 – 8.3 | 4.127 | 0.059 |
| Mean ± SD | 7.17 ± 0.68 | 6.93 ± 0.69 | |||
| Albumin/Globulin ratio | Range | 0.9 – 2.1 | 0.9 – 1.5 | 0.169 | 0.683 |
| Mean ± SD | 1.19 ± 0.26 | 1.22 ± 0.15 | |||
| Prothrombin time (seconds) | Range | 12–18.6 | 12.6 – 21 | 2.269 | 0.140 |
| Mean ± SD | 14.54 ± 1.8 | 15.54 ± 2.34 | |||
| Prothrombin activity (%) | Range | 70 – 100 | 60 – 100 | 0.958 | 0.334 |
| Mean ± SD | 88.75 ± 9.3 | 85.5 ±11.57 |
ALT: Alanine transferase, AST: Aspartate transferase.
There were significantly higher ALT, AST and alkaline phosphatase, significantly lower prothrombin activity and prolonged prothrombin time in Group II compared with Group I after MTX therapy; however serum bilirubin, total proteins, and albumin show no significant differences between Group I and II (Table 3).
Table 3.
Comparison between studied groups as regard liver functions after chemotherapy.
| Parameters | Group I (No=40) | Group II (No=40) | t. Test | p. value | |
|---|---|---|---|---|---|
| Serum ALT (U/L) | Range | 16 – 257 | 142–552 | 44.428 | 0.000* |
| Mean ± SD | 92.93 ± 66.19 | 310.05 ± 129.77 | |||
| Serum AST (U/L) | Range | 13–280 | 110–639 | 29.231 | 0.000* |
| Mean ± SD | 70.15 ± 58.72 | 238.65 ± 126.41 | |||
| Total Serum Bilirubin (mg/dl) | Range | 0.50 – 1.58 | 0.70 – 1.50 | 0.340 | 0.563 |
| Mean ± SD | 0.87 ± 0.28 | 0.92 ± 0.25 | |||
| Direct Bilirubin (mg/dl) | Range | 0.12 – 0.52 | 0.14 – 0.60 | 0.000 | 1.000 |
| Mean ± SD | 0.31 ± 0.11 | 0.31 ± 0.14 | |||
| Indirect Bilirubin (mg/dl) | Range | 0.28 – 1.11 | 0.48 – 1.00 | 0.840 | 0.365 |
| Mean ± SD | 0.56 ± 0.22 | 0.61 ± 0.17 | |||
| Alkaline phosphatase (U/L) | Range | 357–607 | 383–924 | 1.953 | 0.017* |
| Mean ± SD | 456.65 ± 74.08 | 609.05 ± 105.42 | |||
| Albumin (g/dl) | Range | 3.3 – 5.2 | 3.5 – 4.7 | 1.322 | 0.257 |
| Mean ± SD | 4.3 ± 0.6 | 4.11 ± 0.43 | |||
| Total protein (g/dl) | Range | 6–8.7 | 5.7 – 8.4 | 3.725 | 0.061 |
| Mean ± SD | 7.55 ± 0.78 | 7.09 ± 0.75 | |||
| Albumin/Globulin ratio | Range | 1–1.9 | 1.1 – 1.6 | 0.471 | 0.497 |
| Mean ± SD | 1.35 ± 0.26 | 1.40 ± 0.14 | |||
| Prothrombin time (seconds) | Range | 12–20.8 | 18.5 – 21.6 | 20.923 | 0.001* |
| Mean ± SD | 16.75 ± 2.93 | 19.95 ± 1.10 | |||
| Prothrombin activity (%) | Range | 63 – 100 | 60 – 80 | 5.926 | 0.020* |
| Mean ± SD | 77.65 ± 12.83 | 69.7 ± 6.97 |
Significant P value <0.05.
Liver function is the main value of daily serum levels of different parameters of liver functions determined for seven successive days after giving each methotrexate dose.
There were no significant differences between Group I and II as regard kidney functions before chemotherapy while after MTX therapy, there was statistically significant reduction in blood urea and serum creatinine, serum cystatin C and urinary N-acetyl-beta-D-glucosaminidase in Group I compared with Group II (Table 4).
Table 4.
Comparison between studied groups as regard kidney functions before and after chemotherapy.
| Before chemotherapy | Group I (No=40) | Group II (No=40) | t. test | P. value | |
|---|---|---|---|---|---|
| Urea (mg/dl) | Range | 13–62 | 13–69 | 0.281 | 0.599 |
| Mean ± SD | 32.75 ±12.52 | 30.55 ± 13.71 | |||
| Creatinine (mg/dl) | Range | 0.4 – 1.2 | 0.5 – 1.1 | 3.954 | 0. 54 |
| Mean ± SD | 0.72 ± 0.18 | 0.68 ± 0.12 | |||
| Blood urea nitrogen (mgldl) | Range | 9–29 | 8–27 | 2.21 | 0.64 |
| Mean ± SD | 22.11 ± 3.21 | 21.56 ± 2.77 | |||
| Serum Cystatin C (ng/ml) | Range | 600–800 | 612–799 | 4.61 | 0.87 |
| Mean ± SD | 671 ± 142 | 678 ± 139 | |||
| Urinary NAG (ng/ml) | Range | 6.2–9.1 | 6.4–9 | 2.42 | 0.54 |
| Mean ± SD | 7.12 ± 1.9 | 7.25 ± 1.7 | |||
| Mean ± SD | |||||
| After chemotherapy | Group I (No=40) | Group II (No=40) | t. test | P. value | |
| Urea (mg/dl) | Range | 12–42 | 15–41 | 0.683 | 0.049* |
| Mean ± SD | 21.35 ± 6.92 | 33.40 ± 8.67 | |||
| Creatinine (mg/dl) | Range | 0.4 – 1 | 0.4 – 1.4 | 0.932 | 0.034* |
| Mean ± SD | 0.56 ± 0.20 | 0.85 ± 0.18 | |||
| Blood urea nitrogen (mg/dl) | Range | 5–19 | 10–31 | 0.876 | 0.022* |
| Mean ± SD | 16.39 ± 3.45 | 24.98 ± 3.67 | |||
| Serum Cystatin C (ng/ml) | Range | 900–1600 | 1300–3900 | 1.23 | 0.042* |
| Mean ± SD | 1400±230 | 2300±640 | |||
| Urinary NAG (ng/ml) | Range | 8.5–13.4 | 12 – 24 | 3.24 | 0.027* |
| Mean ± SD | 10.3±2.6 | 18.3±5.4 |
NAG = acetyl-beta-D-glucosaminidase.
There were no significant differences between studied groups as regard of continuation of chemotherapy (Table 5).
Table 5.
Effect of Silymarin use on continuation of chemotherapy.
| Group I (No=40) | Group II (No=40) | X2 | P. value | |
|---|---|---|---|---|
| Dose continuation | 30 | 20 | 1.673 | 0.043* |
| Dose reduction † | 9 | 14 | ||
| Stopping of chemotherapy† | 1 | 6 |
Significant.
Persistent elevation of liver enzymes more than two folds for one-month warrants a reduction or discontinuation of methotrexate therapy.13
Discussion
Leukemias are the most common childhood malignancy.34 Methotrexate is widely used in the treatment of various malignancies and non-oncological diseases, and its use is considered of primary importance in the treatment of ALL, even if it is limited by its toxicity.35 Silymarin is a plant extract that has cytoprotective effects against several classes of hepatotoxic and nephrotoxic drugs.35
The aim of the present study was to evaluate the supposed protective effects of Silymarin on methotrexate-induced hepatic and renal toxicity in 80 children with ALL who randomly received, as a part of the treatment protocol, Silymarin (Group I) or a placebo (Group II).
In the current study, after MTX therapy the serum levels of ALT and AST were significantly lower in the group I compared with the group II. These data were in agreement with Ladas et al., 201011 who found that the administration of a 28 days course of Silymarin was associated with a significant reduction in AST and a trend towards a reduction in ALT at Day 56 from the baseline, but not immediately after cessation of supplementation. The latency of reduction of AST and ALT could be due to delayed effects of milk thistle, inadequate dosing, or short duration of supplementation. In our study; there were significantly lower alkaline phosphatase levels in group I compared with group II. This datum parallels with experiments of Ghaffari et al. 201111 who found significantly lower levels of alkaline phosphatase among rats receiving methotrexate and Silymarin compared to the group receiving Methotrexate only.
In the present study, there were significant differences between the studied groups as regard prothrombin time and activity with prolonged prothrombin time in group II compared with group I, but no available studies in the literature for comparison.
In the present study, there were no significant differences in total serum protein and albumin levels and A/G ratio between Group I and II after MTX therapy. This datum is in agreement with Al–Fakhri and Abid, 200513 who, studying the effects of maintenance therapy with MTX and 6–mercaptopurine on the liver of 30 children with ALL, did not find significant changes in total serum proteins, albumin, and A/G ratio.13 In fact, the liver can increase protein and albumin biosynthesis during diseases associated with protein loss, or in the presence of liver cell damage or injury induced by cytotoxic drugs until severe parenchymal damage.7
In the present work, there were no significant differences as regard serum bilirubin between group I and II before and after chemotherapy. These results support the results of Ladas et al., 201011 who studied the effect of Silymarin on liver toxicity in children with ALL during maintenance therapy. Their patients were randomized to receive Silymarin or placebo daily for 28 days starting on the day following chemotherapy. Hepatic toxicity was investigated at Day 0, Day 28, and Day 56 and they found no significant differences in mean serum bilirubin between silymarin and placebo groups. On the other hand Ghaffari et al., 201111 studied the effects of Silymarin on hepatic fibrosis due to MTX in rat and found significantly lower serum bilirubin levels in Silymarin receiving group.
The improvement of hepatic functions in Silymarin group is in agreement with Neuman et al. 199937 who studied the effect of cytochrome
P450 2E1-inducers on MTX-induced cytotoxicity in human hepatocytes, and the silymarin role in preventing this toxicity. The cells were exposed to MTX in the presence of either ethanol or acetaminophen, with or without Silymarin. Ethanol and acetaminophen increased MTX cytotoxicity 2.9 times and 1.9 times, by an increase in IL 6, IL 8 and TNF-alpha and reduce both cGSH and mGSH and thus causing oxidative stress. The addition of silymarin downregulated expression of TNF-alpha and reduced the release of cytokines and abolished this toxicity37, so showing an anti-inflammatory/anti-fibrotic effect.38
The hepatoprotective and antioxidant activity of silymarin concern its ability to inhibit the free radicals that are produced from the metabolism of toxic substances such as ethanol, acetaminophen, and carbon tetrachloride. The generation of free radicals is known to damage cellular membranes and cause lipoperoxidation. Silymarin enhances hepatic glutathione and may contribute to the antioxidant defense of the liver. It has also been shown that silymarin increases protein synthesis in hepatocytes by stimulating RNA polymerase I activity.39,40
The free radical scavenging properties of Silymarin is higher than other antioxidants as Vitamin E and C;41 this could prevent or reduce the onset and progression of chemotherapy-induced hepatotoxicity in patients with ALL.8 Silymarin can also stabilize all cell membranes as it interacts with cell membrane components to prevent any abnormalities in the content of lipid fraction responsible for maintaining normal fluidity and can stimulate tissue regeneration and inhibit the deposition of collagen fibers.41
Silibinin, the most prevalent and active component of Silymarin complex, is able to stimulate DNA-dependent RNA polymerase I and increase rRNA synthesis, and this accelerates the formation of intact rRNA polymerase with resultant formation of new hepatocytes.8,9
In the present study, there were no significant differences between studied groups as regard kidney functions before chemotherapy while there was a significant reduction in renal MTX induced toxicity, evaluated throughout blood urea, serum creatinine, BUN, serum Cystatin C and urinary NAG in Group I compared with Group II.
Serum Cystatin C and urinary NAG provide an early and sensitive marker of occult tubular dysfunction resulting from renal disease or nephrotoxic damage. False positive results are rare, and its activity remains high during active disease or sustained toxic insult but falls to normal on recovery or removal of toxin.32,42
No human studies to compare with but this is in agreement with Dabak and Kocaman 201543 who studied the protective effect of Silymarin against MTX nephrotoxicity in Rats and found a significant reduction in MTX-induced renal damage in Silymarin group.
Conclusion
Silymarin in the dose of 420 mg daily for one week after each dose of MTX improved some hepatic and renal functions in children with ALL who received MTX based chemotherapy protocols.
Recommendations
Extensive multicenter studies on a large number of patients with longer follow-up duration and more advanced methods of assessment of hepatic and renal toxicity are required to confirm the protective effects of Silymarin against MTX-induced hepatic and renal toxicity in patients with ALL who received MTX based chemotherapy.
Acknowledgments
Many thanks for all patients and their families that participated in this research, with hopes for all of them for a good, healthy, and happy life.
Footnotes
Competing interests: The authors have declared that no competing interests exist.
References
- 1.Piatkowska M, Styczynski J. Pediatric acute lymphoblastic leukemia: state of the art and new trends. Journal of Pediatric Sciences. 2010;2(3):22. [Google Scholar]
- 2.Styczynski J, Wysocki M. Methotrexate resistance in acute leukemias. Pol Merkur Lekarski. 2001 Aug;11(62):175–9. [PubMed] [Google Scholar]
- 3.Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–739. doi: 10.1056/NEJMra052270. [DOI] [PubMed] [Google Scholar]
- 4.Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. Journal of the European Academy of Dermatology and Venereology. 2011;25(7):758–764. doi: 10.1111/j.1468-3083.2010.03932.x. [DOI] [PubMed] [Google Scholar]
- 5.Widemann BC, Adamso PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694–703. doi: 10.1634/theoncologist.11-6-694. [DOI] [PubMed] [Google Scholar]
- 6.Moss RW. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integr Cancer Ther. 2006;5:63–82. doi: 10.1177/1534735405285882. [DOI] [PubMed] [Google Scholar]
- 7.Hagag AA, AbdElaal AM, Elfaragy MS, Hassan SM, Elzamarany E. Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia. Infect Disorder Drug Targets. 2015;15(1):64–71. doi: 10.2174/1871526515666150320161440. [DOI] [PubMed] [Google Scholar]
- 8.Ramasamy K, Agarwal R. Multitargeted therapy of cancer by Silymarin. Cancer Letters. 2008;269(2):352–362. doi: 10.1016/j.canlet.2008.03.053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. J Gastroenterol Hepatol. 2001;61(14):2035–2063. doi: 10.2165/00003495-200161140-00003. [DOI] [PubMed] [Google Scholar]
- 10.Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA. 2010 Mar 30;107(13):5995–9. doi: 10.1073/pnas.0914009107. Epub 2010 Mar 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ghaffari AR, Noshad H, Ostadi A, Ghojazadeh M, Asadi P. The effect of milk thestile on hepatic fibrosis due to methotrexate in rat. Hepat Mon. 2011;11(6):464–468. [PMC free article] [PubMed] [Google Scholar]
- 12.Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, Rheingold SR, Kelly KM. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL) Cancer. 2010 Jan 15;116(2):506–513. doi: 10.1002/cncr.24723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ilham Al–Fakhri F, Firas Abid T. Effect of maintenance therapy for childhood with ALL by combination of methotrexate and 6-mercaptopurine on the liver. Al-Mustansiriyah Journal for Pharmaceutical Sciences. 2005;2(2):18–23. [Google Scholar]
- 14.Pui CH. Acute lymphoplastic leukemia: Overview. In: Lichtman MA, Beulter E, Seligsonn U, Kipps TO, Kaushansky K, Prchal J, editors. William Textbook of Hematology. 17th edition. Vol. 91. New York: McGraw-Hill Companies, Inc; 2007. pp. 1141–53. Chapter 91. Part XI: Neoplastic Lymphoid Diseases. [Google Scholar]
- 15.Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, Pullen J, Pettenati M, Carroll A, Shuster JJ, Camitta B. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from the Children’s Oncology Group Study P9201. Blood. 2007 Aug 15;110(4):1105–11. doi: 10.1182/blood-2006-12-061689. Epub 2007 Apr 18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, Freyer DR, Mattano LA, Jr, Hastings CA, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, Edens C, Gaynon PS. Early post induction intensification therapy improves survival for children and adolescents with high risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2008 Mar 1;111(5):2548–55. doi: 10.1182/blood-2007-02-070342. Epub 2007 Nov 26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lanzkowsky PH. Leukemias. In: Philip Lanzkowsky., editor. Manual of Pediatric Hematology and Oncology. 4th ed. Vol. 17. Churchill livingstane; Nek, London, Madrid: 2011. pp. 518–566. [Google Scholar]
- 18.Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL. Childhood T cell acute lymphoblastic leukemia. The Dana-Farber Cancer Institute. Acute Lymphoblastic Leukemia Consortium experience. J Clin Oncol. 2003 Oct 1;21(19):3616–22. doi: 10.1200/JCO.2003.10.116. [DOI] [PubMed] [Google Scholar]
- 19.Rahiem Ahmed YAA, Hasan Y. Prevention and Management of High Dose Methotrexate Toxicity. J Cancer Sci Ther. 2013;5:106–112. doi: 10.4172/1948-5956.1000193. [DOI] [Google Scholar]
- 20.Hagag Adel A, Elfrargy Mohamed S, Gazar Rana A, Abd El-Lateef Aml Ezzat. Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia Mediterr. J Hematol Infect Dis. 2013;5(1):e2013065. doi: 10.4084/mjhid.2013.065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Margolin JF, Rabin KR, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 6th edition. Philadelphia: 2011. pp. 518–565. [Google Scholar]
- 22.Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization Classification neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November. J Clin Oncol. 1999 Dec;17(12):3835–49. doi: 10.1200/JCO.1999.17.12.3835. [DOI] [PubMed] [Google Scholar]
- 23.Pui CH. Acute lymphoblastic leukemia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams Hematology. Vol. 97. New York: McGraw-Hill; 2012. pp. 1141–1162. [DOI] [Google Scholar]
- 24.Catovsky D, Hoffbrand AV. Acute myeloid leukaemia. In: Hoffbrand AV, Lewis SM, editors. Postgraduate Haematology. 5th edition. Oxford, UK: Reed Educational and Professional Publishing Ltd; 2005. pp. 509–524. [Google Scholar]
- 25.George-Gay B, Parker K. Understanding the Complete Blood Count with Differential. J Perianesth Nurs. 2003;18(2):96–114. doi: 10.1053/jpan.2003.50013. quiz 115–7. [DOI] [PubMed] [Google Scholar]
- 26.Yang DT, Robetorye RS, Rodgers GM. Home prothrombin time monitoring: A literature analysis. Am J Hematol. 2004 Oct;77(2):177–86. doi: 10.1002/ajh.20161. [DOI] [PubMed] [Google Scholar]
- 27.Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chem Acta. 1997;258(1):21–30. doi: 10.1016/S0009-8981(96)06447-9. [DOI] [PubMed] [Google Scholar]
- 28.Gella FJ, Olivella T, Cruz Pastor M, Arenas J, Moreno R, Durban R, Gomez JA. A simple procedure for the routine determination of aspartate aminotransferase and alanine aminotransferase with pyridoxal phosphate. Clin Chem Acta. 1985;153(3):241–47. doi: 10.1016/0009-8981(85)90358-4. [DOI] [PubMed] [Google Scholar]
- 29.Kaplan A. Clin Chem. The CV Mosby Co.; St Louis. Toronto. Princeton: 1984. Urea; pp. 1257–1260.pp. 437pp. 418 Kaplan A. et al. [Google Scholar]
- 30.Hossain MA, Emara M, El Moselhi H, Shoker A. Comparing measures of cystatin C in human sera by three methods. Am J Nephrol. 2009;29(5):381–91. doi: 10.1159/000168486. [DOI] [PubMed] [Google Scholar]
- 31.Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200–8. doi: 10.1111/j.1752-8062.2008.00053.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Assal Heba S, Salwa Tawfeek, Rasheed Enas A, Dali El-Lebedy, Thabet Eman H. Serum Cystatin C and Tubular Urinary Enzymes as Biomarkers of Renal Dysfunction in Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes. 2013 Jul 31;6:7–13. doi: 10.4137/CMED.S12633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Petrie A, Sabin C. Medical statistics at a glance. 2nd edition. 1. Vol. 978. Blackwell publishing; Oxford: 2005. pp. 4051–8051. [Google Scholar]
- 34.Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; Childhood cancer. based on November 2012 SEER data submission, posted to the SEER web site 2013. [Google Scholar]
- 35.Ramphal R, Meyer R, Schacter B, Rogers P, Pinkerton R. Active therapy and models of care for adolescents and young adults with cancer. Cancer. 2011;117(S10):2316–2322. doi: 10.1002/cncr.26048. [DOI] [PubMed] [Google Scholar]
- 36.Bahmani M, Shirzad H, Rafieian S, Rafieian-Kopaei M. Silybum marianum: Beyond Hepatoprotection. Journal of evidence -Based Complementary and Alternative Medicine. 2015 doi: 10.1177/2156587215571116. 2156587215571116. [DOI] [PubMed] [Google Scholar]
- 37.Neuman M, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem. 1999 Oct;32(7):519–36. doi: 10.1016/s0009-9120(99)00052-1. 25. [DOI] [PubMed] [Google Scholar]
- 38.Abdel-Moneim AM, Al-Kahtani MA, El-Kersh MA, Al-Omair MA. FreeRadical-Scavenging, Anti-Inflammatory/Anti-Fibrotic and Hepatoprotective Actions of Taurine and Silymarin against CCl4 Induced Rat Liver Damage. PLoS One. 2015 Dec 11;10(12):e0144509. doi: 10.1371/journal.pone.0144509. eCollection 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Vargas-Mendoza Nancy, Madrigal-Santillán Eduardo, Morales-González Ángel, Esquivel-Soto Jaime, Esquivel-Chirino Cesar, García-Luna y González-Rubio Manuel, Gayosso-de-Lucio Juan A, Morales-González José A. Hepatoprotective effect of silymarin. World J Hepatol. 2014 Mar 27;6(3):144–149. doi: 10.4254/wjh.v6.i3.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Morales-González JA, Madrigal-Santillán E, Morales-González Á, Bautista M, Gayosso-Islas E, Sánchez-Moreno C. What is Known Regarding the Participation of Factor Nrf-2 in Liver Regeneration? Cells. 2015 Jun;4(2):169–177. doi: 10.3390/cells4020169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Pradhan S, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian Journal of Medical Research. 2006;124(5):491. [PubMed] [Google Scholar]
- 42.Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol. 1992;38(Suppl 1):S14–9. [PubMed] [Google Scholar]
- 43.Dabak DO, Kocaman N. Effects of silymarin on MTX induced nephrotoxicity in rats. Ren Fail. 2015 May;37(4):734–9. doi: 10.3109/0886022X.2015.1012984. Epub 2015 Feb 24. [DOI] [PubMed] [Google Scholar]